Clinical trial NCT05422365: Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
Official title: Open, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of Bioven, Manufactured by Biopharma Plasma LLC, in Adult Patients With Chronic Primary Immune Thrombocytopenia (ITP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Primary Immune Thrombocytopenia
Keywords: IVIG
ITP
immunomodulatory therapy
intravenous immunoglobulin
chronic primary immune thrombocytopenia
Lead sponsor: Biopharma Plasma LLC
Sponsor class: INDUSTRY
First posted: 2022-06-16
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open, multicenter, international, uncontrolled
Primary purpose: TREATMENT

Brief summary: The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of "chronic" means that the disease lasts more than 12 months.

Patients included in the study will receive Bioven, 10% solution for infusion according to the protocol for the use of IVIG in ITP - at a dose of 0.8-1.0 g / kg 1 time per day for 2 consecutive days, the course dose of 1.6-2.0 g / kg according to the "Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG)", rev. 3, 28 June 2018. After administration of the investigational drug, patients will be under medical supervision for 28 days.

The stay of patients in the study - at least 4 weeks.

Detailed description: The investigational drug, IVIG, is used for immunomodulatory therapy in the treatment of autoimmune diseases.

The study will involve patients with chronic immune thrombocytopenia. This autoimmune disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of "chronic" means that the disease lasts more than 12 months.

Screening stage The patient or her legal representative must sign an informed consent. After the informed consent signing procedure, the patient is screened and assessed for compliance with the inclusion and non-inclusion (exclusion) criteria.

Clinical stage After the patient is included in the study, according to the protocol, he/she is hospitalized and the study drug is administered at a dose of 0.8-1.0 g/kg once a day for 2 days (the course dose is 1.6-2.0 g/kg). The next day after the administration of the drug, the patient undergoes blood sampling to determine the level of platelets, the level of immunoglobulin G (IgG) and the Coombs test. This procedure will also be carried out on days 7, 14, 21 and 28 after the first injection of the drug to monitor the patient's performance.

The final stage The blood sampling procedure to determine the above indicators will be carried out on days 7, 14, 21, and 28 after the first administration of the drug to monitor the patient's performance.

Eligibility criteria: Inclusion criteria:

* Signed Patient Informed Consent Form for participation in the study;
* Men and women aged 18-65;
* Confirmed primary chronic ITP (lasting \> 12 months since diagnosis);
* A full blood count should be normal except for the isolated thrombocytopenia. Patients with low hemoglobin levels (but above 90 g / l) may be included if there are symptoms of bleeding;
* If bleeding symptoms are diagnosed, the reticulocyte count should be measured;
* Platelet count \<30 x 109 / L;
* If the patient is taking corticosteroids, the treatment regimen/dose should be stable (at least 2 weeks prior to screening);
* Negative pregnancy test (for women of child-bearing potential);
* Willingness to use effective and reliable methods of contraception throughout the entire study period;
* The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant;
* Ability, according to the researcher, to follow all the requirements of the study protocol;

Exclusion criteria:

* Known intolerance to plasma and immunoglobulin preparations;
* Drug allergy or hypersensitivity to immunoglobulin preparations;
* Confirmed deficiency of immunoglobulin A (IgA) and antibodies to IgA.
* Contraindications to immunoglobulin administration according to the instructions for medical use;
* Pregnancy and lactation;
* Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal);
* Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex;
* Severe cardiovascular insufficiency (HF III);
* History of thrombosis or presence of significant risk factors for thrombosis.
* Patients with preventive splenectomy;
* Hemostatic disorders other than chronic thrombocytopenia;
* Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system;
* Proven case of primary immunodeficiency;
* Secondary immune thrombocytopenia;
* Virus infections (Epstein-Barr, Cytomegalovirus, Parvovirus, Hepatitis B and C);
* Documented HIV infection
* Positive reaction of Wassermann (RW) test result;
* Systemic immunopathological diseases (rheumatic diseases, nephritis, etc.);
* Oncological diseases;
* Diabetes mellitus;
* Thyroid diseases;
* History of mental illness;
* Known drug addiction;
* Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study;
* The need to prescribe drugs that are incompatible with the administration of the drug in this study: other immunoglobulin preparations in addition to the study drug, cytostatic drugs, monoclonal antibodies, Avatrombopag);
* Experimental treatment (e.g. Rituximab therapy) for 3 months prior to screening);
* Blood transfusions or transfusions of blood products in the last 6 months prior to inclusion in the study;
* Administration of IVIG 30 days prior to screening;
* Participation in any other study currently or within the last 30 days;

Criteria for exclusion of subjects (discontinuation of treatment with the study drug):

* Patient's wish
* Occurrence of severe and/or unexpected Adverse events (AE) or Adverse reactions (AR) in patient during the study, that require discontinuation of the drug;
* The need to prescribe drugs prohibited in this study.
* Significant deterioration of the patient's condition during the study period;
* Failure of the patient to adhere to the treatment regimen;
* Failure of the patient to follow the procedures established under the protocol;

Primary outcomes:
measure: Part (Percent) of Patients With Response (R)
timeFrame: 28 days after first administration of the study drug
Secondary outcomes:
measure: Part (Percent) of Patients With Complete Response (CR)
timeFrame: 28 days after first administration of the study drug
measure: Part (Percent) of Patients With no Response (NR)
timeFrame: 28 days after first administration of the study drug
measure: Part (Percent) of Patients With Loss of Response (R)
timeFrame: 28 days after first administration of the study drug
measure: Part (Percent) of Patients With Loss of Complete Response (CR)
timeFrame: 28 days after first administration of the study drug
measure: Time (in Days) From Treatment Start to Response (R)
timeFrame: 28 days after first administration of the study drug
measure: Time (in Days) From Treatment to Complete Response (CR)
timeFrame: 28 days after first administration of the study drug
measure: Duration (in Days) of Response (R)
timeFrame: 28 days after first administration of the study drug
measure: Duration (in Days) of Complete Response (CR)
timeFrame: 28 days after first administration of the study drug
Other outcomes:
measure: Frequency (Percent) of Adverse Events
timeFrame: 28 days after first administration of the study drug
measure: Frequency of Serious Adverse Events
timeFrame: 28 days after first administration of the study drug
Locations:
city: Dnipro
country: Ukraine
facility: Municipal non-profit enterprise "City Clinical Hospital No. 4" of the Dnipro City Council
city: Khmelnytskyi
country: Ukraine
facility: Municipal non-profit enterprise "Khmelnytskyi Regional Hospital" of the Khmelnytskyi Regional Council
city: Kropyvnytskyi
country: Ukraine
facility: Municipal Non-Profit Enterprise "Kirovohrad Regional Hospital of the Kirovohrad Regional Council"
city: Kyiv
country: Ukraine
facility: Medical Center "OK!Clinic+" of the Company with Limited Liability "International Institute of Clinical Research"
city: Kyiv
country: Ukraine
facility: Municipal Non-Profit Enterprise of Kyiv Regional Council "Kyiv Regional Oncology Dispensary"
city: Kyiv
country: Ukraine
facility: Municipal non-profit enterprise "Kyiv City Clinical Hospital No. 9" of the executive body of the Kyiv City Council (Kyiv City State Administration)
city: Kyiv
country: Ukraine
facility: "Arensia Exploratory Medicine" Limited Liability Company Medical Center
city: Lviv
country: Ukraine
facility: State Institution "Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine"
city: Rivne
country: Ukraine
facility: Minicipal enterprise "Rivne regional clinical hospital" of Rivne regional council
city: Sumy
country: Ukraine
facility: Municipal Non-Profit Enterprise of Sumy Regional Council "Sumy Regional Clinical Hospital"
city: Ternopil
country: Ukraine
facility: Municipal non-profit enterprise "Ternopil University Hospital" of Ternopil Regional Council
city: Uzhhorod
country: Ukraine
facility: Municipal Non-Profit Enterprise "Zakarpattia Regional Clinical Hospital named after Andriy Novak" of Zakarpattia Regional Council
Study officials:
References: